Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YD312 (Imatinib) in Diabetic Macular Edema
NCT03635814Phase 2Unknown
- Sponsor
- YD Global Life Science
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of imatinib in diabetic macular edema (DME) (4 arms), sponsored by YD Global Life Science. Primary endpoint: Change in ETDRS Best Corrected Visual Acuity Letter Score at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03635814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635814.